"You can find that team at Ironwood Cancer & Research Centers. With community-based centers strategically located throughout the Metro Phoenix area, Ironwood offers advanced therapies and a multi-disciplinary approach usually associated with large academic centers – but with a personalized touch recognizing the individual needs of the patient. Studies have shown the importance of a multi-disciplinary approach in effectively treating cancer. We spare you time and worry simply by having all the doctors, therapists, and resources you need in one convenient location, eliminating the delays and miscommunication."

During the past decade, Ironwood Cancer and Research Centers conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 28 clinical trials were completed, i.e. on average, 75.7% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 14 clinical trials were completed. i.e. 82.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Ironwood Cancer and Research Centers" #1 sponsor was "Novartis Pharmaceuticals" with 13 trials, followed by "Daiichi Sankyo, Inc." with 4 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored, "Boehringer Ingelheim" with 3 trials sponsored and "Celgene" with 3 trials sponsored. Other sponsors include 29 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Ironwood Cancer and Research Centers" #1 collaborator was "AstraZeneca" with 4 trials as a collaborator, "Merck Sharp & Dohme LLC" with 4 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator, "EMD Serono" with 1 trials as a collaborator and "Flatiron Health, Inc.; Foundation Medicine, Inc." with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Ironwood Cancer and Research Centers" are "Breast Cancer" (12 trials), "Metastatic Breast Cancer" (7 trials), "Breast Neoplasms" (4 trials), "Non-small Cell Lung Cancer" (3 trials) and "Carcinoma, Non-Small-Cell Lung" (2 trials). Many other conditions were trialed in "Ironwood Cancer and Research Centers" in a lesser frequency.

Most popular intervention types in "Ironwood Cancer and Research Centers" are "Drug" (56 trials), "Biological" (5 trials), "Other" (3 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (11 trials), "Carboplatin" (8 trials), "Gemcitabine" (6 trials), "Paclitaxel" (6 trials) and "Fulvestrant" (5 trials). Other intervention names were less common.

The vast majority of trials in "Ironwood Cancer and Research Centers" are 46 trials for "All" genders, 13 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Ironwood Cancer and Research Centers". undefined are not yet recruiting, 11 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Ironwood Cancer and Research Centers, 1 suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Ironwood Cancer and Research Centers, 0 "Phase 1" clinical trials were conducted, 20 "Phase 2" clinical trials and 37 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 1 trials that are defined as “Not Applicable".